Zydus receives FDA final approval for Diroximel fumarate delayed-release capsules, 231 mg

Diroximel fumarate delayed-release capsules, 231 mg, are indicated for the treatment of relapsing forms of multiple sclerosis

Zydus Lifesciences secures FDA tentative approval for Olaparib tablets

Olaparib is indicated for the treatment of certain types of ovarian, breast, pancreatic, and prostate cancers

Zydus receives FDA’s tentative approval for Budesonide delayedrelease capsules, 4 mg

Budesonide is indicated for mild to moderate active Crohn's disease involving the ileum and/or the ascending colon in adults and children 8 years of age and olde

Zydus receives approval from Health Canada for Liothyronine tablets 5 mcg and 25 mcg

Liothyronine tablets will be manufactured at Zydus' plant in Ahmedabad SEZ

Zydus receives final approval from USFDA for Prucalopride Tablets

Prucalopride is prescribed for chronic idiopathic constipation

Sigachi begins construction work for MCC capacity expansion at Dahej

With this addition, the company’s total Installed MCC Capacity will rise to 30,000 MTPA

Zydus receives NOC from Health Canada for ZDS-Varenicline Tablets 0.5 &1 mg

This is the group’s first NoC approval in Canada

Zydus receives tentative approval from USFDA for Ibrutinib tablets

Ibrutinib tablets will be produced at Zydus Lifesciences Ltd (SEZ), Ahmedabad

Zydus receives final approval from USFDA for Celecoxib Capsules

Celecoxib is a nonsteroidal anti-inflammatory drug

USFDA concludes inspection at Zydus' oncology injectable plant at Ahmedabad